Why Med-Tech Firms, Venture Capitalists and Bankers Are Investing in Psychedelic Medicine

Global interest and investment in psychedelic medicine companies is accelerating. However, these treatments are not like typical medicines. The patient experience and clinical care model is intense and also deeply, and necessarily, intertwined. So, the question arises, how can we develop care delivery models for these treatments that are safe, effective but also commercially viable? We will explore these themes with clinical service partner Emyria. We will explore how we are approaching these challenges and learn from Emryia’s experience creating an evidence-generating care model for medicinal cannabis.

This FREE webinar will explore:

1. An overview of the psychedelic industry and its growth globally and locally
2. The different types of for-profit commercial entities developing
3. The need for these treatments in Australia and how we are actively preparing for their delivery
4. Importance of working with a therapist the patient can trust and how set/setting play a role
5. How the physical infrastructure of the clinic affects the patient experience. The importance of investing in the healing space
6. The importance of co-creating robust and ethically-sourced clinical data with patients to ensure we learn from every patient